DSC Advisors LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
DSC Advisors LP
CRD #158312
SEC #801-73330
CIK #0001299434
AUM
Employees 8 (62% Investors, 0% Brokers)
Fees
Minimum
Phone312-915-2400
Address900 N Michigan Ave
Chicago, IL 60611
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
70056042028014002005201120182025
Fees and Compensation — Form ADV Part 2A (1/3/2020) [Brochure]
Item 5 – Fees and Compensation
Management Fees; Performance-Based Compensation

We generally receive a management fee calculated as a fixed percentage of the value of the
assets we manage. In addition, and as further described in Item 6, we or our affiliates are
entitled to additional compensation in the form of an incentive allocation based on the
performance achieved for a client over a specified measurement period, generally, a fiscal
year (collectively, the management fee and incentive allocation, if applicable, are referred to
herein as “Fees”). Our Fees are deducted from the Funds’ assets. Our fee schedule is omitted
since this brochure is only delivered to qualified purchasers as defined in Section 2(a) (51)
(A) of the Investment Company Act of 1940, as amended. Fees applicable to the Funds are
described in each Fund’s applicable offering documents.

With regard to any of the Fees, we are generally permitted under the terms of a Fund’s
governing documents to reduce or waive, in our sole discretion, our Fees for underlying
investors in any of the Funds. For example, we can reduce the Fees applicable to investments
in any of the Funds by certain large, strategic, or affiliated investors. For the year ended
December 31, 2018, we have waived certain components of the Fees for certain affiliated
investors.

We can launch or manage other funds or accounts with higher or lower fees and/or different
compensation structures. To the extent the Fund invests in any affiliated funds, the Fund will
receive the benefit of any appropriate management fee offsets. Different client facts and
circumstances, including the client’s investment strategy, liquidity profile and prevailing
market terms, will be considered in determining applicable Fees.

Costs and Expenses

In addition to the Fees discussed above, investors in the Funds will bear indirectly the fees
and expenses charged to the Funds. While those fees will vary, they typically include, but are
not limited to the following: the Feeder Fund’s applicable pro rata portion of the Master
Fund’s expenses relating to its investment activities, including brokerage commissions,
prime brokerage fees, “bid-ask” spreads, mark-ups, interest expenses, stock loan expenses,
costs incurred by errors committed in trading securities barring willful misconduct, gross
negligence, or bad faith and other transactional charges. The Funds also will directly bear
certain expenses relating to cash management and certain administrative costs, such as legal,
accounting, audit, tax preparation, consulting and custodial fees and expenses.

The Feeder Fund’s offering and governing documents detail the costs and expenses that are
the responsibility of the applicable Fund, as well as certain overhead costs and expenses that
generally are our responsibility.
Account Minimums and Types of Clients — Form ADV Part 2A (1/3/2020) [Brochure]
Item 7 – Types of Clients
The Adviser currently provides discretionary investment advice to several related private
investment funds, including private investment partnerships and foreign investment
companies. Interests in the Funds are offered pursuant to applicable exemptions from
registration under the Securities Act of 1933, as amended. Investors in the Funds are subject
to qualification standards. Investors in the Funds may include, among others, pension plans,
foundations, funds of funds, family offices, trusts, other institutional investors and high net
worth individuals. The minimum initial investment in the Funds is generally $1 million,
subject to change or waiver at the discretion of the Adviser and/or the Fund’s Board of
Directors, if applicable.

In addition to the Funds, we could in the future provide advisory services to other private
investment funds or other clients.
Sector Form 13F Holdings Value ($M)
Ehealth Inc 2.4
Kornit Digital Ltd 1.5
Menlo Therapeutics Inc 1.3
Facebook Inc 0.6
Microsoft Corp 0.5
Alphabet Inc 0.5
Mastercard Inc 0.4
Visa Inc 0.4
Netflix Inc 0.4
Oracle Corp 0.3
View All
Holdings by Sector ($M)
90072054036018002013201720212025
Type Form D Funds Date Sold AUM
HF DSC Pe/VC Index Fund LP [2016-11-03] 5.1 M 5.0 M
Filed 2021-04-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Commission $38,429 · Net Assets Decline to Disclose
HF DSC Thomson Reuters PE Index Master Fund LP [2014-03-28] 5.3 M 14.9 M
Filed 2021-04-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF DSC Thomson Reuters VC Index Master Fund LP [2013-03-25] 10.8 M 17.1 M
Filed 2026-03-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Delaware Street Capital Master Fund LP 2012-02-10 380.9 M
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 2 380.9
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 2 380.9
By Discretionary
Discretionary 2 380.9
Non-Discretionary 0 0.0
Total 2 380.9
By Non-United States Persons
Non-United States Persons 234.8
United States Persons 146.1
Total 2 380.9
Form D Directors Role # Filings # Firms 2011 - 2026
Andrew Bluhm Executive Officer 10 3
David Nietfeldt Executive Officer 6 3
Arthur Bushonville Executive Officer 3 2
Dsc QG Partners LLC Executive Officer 3 2
Steve Bohn Executive Officer 3 2
Amy Close Executive Officer 3 2
Dscqg PR LLC Executive Officer 3 2
Jeffrey Knupp Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001299434]
3 [0001299434]
4 [0001299434]
SC 13D [0001299434]
Form 13D/13G Filer Form 13D/13G Subject Filed
DSC Advisors LP BioScrip Inc [2014-12-30]
Firm Profile (Form ADV)
Discretionary AUM$0.2B
ServesInstitutional
Fund TypesHedge Fund
Form 3/4/5 Subject 2011 - 2026
DSC Advisors LLC
Delaware Street Capital Master Fund LP
Bluhm Andrew G
DSC Managers LLC
DSC Advisors LP
Zevra Therapeutics Inc
Delaware Street Capital L P
Neos Therapeutics Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
2018-10-05 Buy 2,000,000 $3.00 6,000,000
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
2018-07-30 Buy 304,283 $4.00 1,217,132
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
2017-09-14 Buy 138,857 $3.30 458,228
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
2017-09-13 Buy 186,831 $3.25 607,201
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
2017-09-13 Buy 200 $3.25 650
Neos Therapeutics Inc NEOS
Series C Preferred Stock · derivative
2015-07-28 Conversion 34,153
Neos Therapeutics Inc NEOS
Preferred Stock Warrant (Right to Buy) · derivative
2015-07-28 Option exercise 170,766
Neos Therapeutics Inc NEOS
Series C Preferred Stock · derivative
2015-07-28 Conversion 1,496,521
Neos Therapeutics Inc NEOS
Series B-1 Preferred Stock · derivative
2015-07-28 Conversion 493,982
Neos Therapeutics Inc NEOS
Series B Preferred Stock · derivative
2015-07-28 Conversion 153,009
Neos Therapeutics Inc NEOS
Common Stock
2015-07-28 Conversion 205,825
Neos Therapeutics Inc NEOS
Common Stock
2015-07-28 Conversion 623,550
Neos Therapeutics Inc NEOS
Common Stock
2015-07-28 Conversion 14,230
Neos Therapeutics Inc NEOS
Common Stock
2015-07-28 Conversion 63,753
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com